{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:59:45Z","timestamp":1792605585957,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s11899-021-00633-5","type":"journal-article","created":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T14:04:09Z","timestamp":1620223449000},"page":"162-171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["MRD Assessment in Multiple Myeloma: Progress and Challenges"],"prefix":"10.1007","volume":"16","author":[{"given":"Luca","family":"Bertamini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"D\u2019Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8619-412X","authenticated-orcid":false,"given":"Francesca","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,5]]},"reference":[{"key":"633_CR1","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"\u2022\u2022 Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4:5988\u201399 A recent meta-analysis on around 8000 patients from different MRD studies, confirming the important prognostic impact of the achievement of MRD negativity, regardless of the adopted method (next-generation sequencing [NGS] or multiparameter flow cytometry [MFC]), time point, and setting (diagnosis or relapse).","journal-title":"Blood Adv"},{"key":"633_CR2","doi-asserted-by":"publisher","unstructured":"Oliva S, D\u2019Agostino M, Boccadoro M, Larocca A. Clinical applications and future directions of minimal residual disease testing in multiple myeloma. Front Oncol. 2020;10. https:\/\/doi.org\/10.3389\/fonc.2020.00001.","DOI":"10.3389\/fonc.2020.00001"},{"key":"633_CR3","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346.","journal-title":"Lancet Oncol"},{"key":"633_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","volume":"35","author":"LJ Costa","year":"2021","unstructured":"\u2022\u2022 Costa LJ, Derman BA, Bal S, et al. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2021;35:18\u201330 An international expert consensus on how to report MRD analysis, to foster the standardization and comparison among different studies.","journal-title":"Leukemia"},{"key":"633_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/cyto.b.21265","volume":"90","author":"J Flores-Montero","year":"2016","unstructured":"Flores-Montero J, de Tute R, Paiva B, Perez JJ, B\u00f6ttcher S, Wind H, et al. Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom. 2016;90:61\u201372.","journal-title":"Cytometry B Clin Cytom"},{"key":"633_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/cyto.b.21249","volume":"90","author":"M Stetler-Stevenson","year":"2016","unstructured":"Stetler-Stevenson M, Paiva B, Stoolman L, Lin P, Jorgensen JL, Orfao A, et al. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. Cytometry B Clin Cytom. 2016;90:26\u201330.","journal-title":"Cytometry B Clin Cytom"},{"key":"633_CR7","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","volume":"31","author":"J Flores-Montero","year":"2017","unstructured":"Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garc\u00eda-S\u00e1nchez O, B\u00f6ttcher S, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31:2094\u2013103.","journal-title":"Leukemia"},{"key":"633_CR8","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1200\/JCO.19.01231","volume":"38","author":"B Paiva","year":"2020","unstructured":"Paiva B, Puig N, Cedena MT, Rosi\u00f1ol L, Cord\u00f3n L, Vidriales MB, et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol. 2020;38:784\u201392.","journal-title":"J Clin Oncol"},{"key":"633_CR9","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1200\/JCO.2009.23.7172","volume":"28","author":"M Ladetto","year":"2010","unstructured":"Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol. 2010;28:2077\u201384.","journal-title":"J Clin Oncol"},{"key":"633_CR10","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/cncr.31854","volume":"125","author":"M Gambella","year":"2019","unstructured":"Gambella M, Omed\u00e9 P, Spada S, Muccio VE, Gilestro M, Saraci E, et al. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: a pooled analysis. Cancer. 2019;125:750\u201360.","journal-title":"Cancer"},{"key":"633_CR11","first-page":"391","volume":"28","author":"N Puig","year":"2014","unstructured":"Puig N, Sarasquete ME, Balanzategui A, Mart\u00ednez J, Paiva B, Garc\u00eda H, et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry Leukemia. 2014;28:391\u20137.","journal-title":"A comparative analysis with flow cytometry Leukemia"},{"key":"633_CR12","doi-asserted-by":"publisher","first-page":"e425","DOI":"10.1200\/EDBK_159088","volume":"36","author":"H Avet-Loiseau","year":"2016","unstructured":"Avet-Loiseau H. Minimal residual disease by next-generation sequencing: pros and cons. Am Soc Clin Oncol Educ B. 2016;36:e425\u201330.","journal-title":"Am Soc Clin Oncol Educ B"},{"key":"633_CR13","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","volume":"132","author":"A Perrot","year":"2018","unstructured":"Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132:2456\u201364.","journal-title":"Blood"},{"key":"633_CR14","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","volume":"20","author":"J Hillengass","year":"2019","unstructured":"Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019;20:e302\u201312.","journal-title":"Lancet Oncol"},{"key":"633_CR15","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","volume":"18","author":"M Cavo","year":"2017","unstructured":"Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18:e206\u201317.","journal-title":"Lancet Oncol"},{"key":"633_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","volume":"34","author":"M Bhutani","year":"2020","unstructured":"Bhutani M, Foureau DM, Atrash S, Voorhees PM, Usmani SZ. Extramedullary multiple myeloma. Leukemia. 2020;34:1\u201320. https:\/\/doi.org\/10.1038\/s41375-019-0660-0.","journal-title":"Leukemia."},{"key":"633_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-00296-y","volume":"8","author":"L Rasche","year":"2017","unstructured":"Rasche L, Chavan SS, Stephens OW, et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun. 2017;8:1\u201310.","journal-title":"Nat Commun"},{"key":"633_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","volume":"130","author":"L Rasche","year":"2017","unstructured":"Rasche L, Angtuaco E, McDonald JE, et al. Low expression of hexokinase-2 is associated with false-negative FDG\u2013positron emission tomography in multiple myeloma. Blood. 2017;130:30\u20134.","journal-title":"Blood"},{"key":"633_CR19","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.7150\/thno.20491","volume":"7","author":"C Lapa","year":"2017","unstructured":"Lapa C, Garcia-Velloso MJ, L\u00fcckerath K, Samnick S, Schreder M, Otero PR, et al. 11C-Methionine-PET in multiple myeloma: a combined study from two different institutions. Theranostics. 2017;7:2956\u201364.","journal-title":"Theranostics"},{"key":"633_CR20","doi-asserted-by":"crossref","unstructured":"Oliva S, Genuardi E, Belotti A, et al (2020) Multiparameter flow cytometry (MFC) and next generation sequencing (NGS) for minimal residual disease (MRD) evaluation: Results of the FORTE trial in newly diagnosed multiple myeloma (MM). J Clin Oncol 38:Abstract #8533 [ASCO 2020 Annual Meeting].","DOI":"10.1200\/JCO.2020.38.15_suppl.8533"},{"key":"633_CR21","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1016\/j.clml.2019.09.005","volume":"19","author":"H Avet-Loiseau","year":"2019","unstructured":"Avet-Loiseau H, Bene MC, Wuilleme S, Corre J, Attal M, Arnulf B, et al. Concordance of post-consolidation minimal residual disease rates by multiparametric flow cytometry and next-generation sequencing in CASSIOPEIA. Clin Lymphoma, Myeloma Leuk. 2019;19:e3\u20134.","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"key":"633_CR22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41408-020-00377-0","volume":"10","author":"A Medina","year":"2020","unstructured":"Medina A, Puig N, Flores-Montero J, Jimenez C, Sarasquete ME, Garcia-Alvarez M, et al. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. Blood Cancer J. 2020;10:108.","journal-title":"Blood Cancer J"},{"key":"633_CR23","unstructured":"Zamagni E, Nanni C, Gay F, et al (2020) MRD evaluation by PET\/CT according to Deauville criteria combined with bone marrow techniques in newly diagnosed transplant eligible multiple myeloma patients enrolled in the phase II FORTE trial. HemaSphere 4:60 [Abstract #S207, EHA 2020 25th Congress]."},{"key":"633_CR24","doi-asserted-by":"crossref","unstructured":"Bertamini L, Grasso M, D\u2019Agostino M, et al (2020) Poor prognosis of multiple myeloma predicted by high levels of circulating plasma cells is independent from other high-risk features but is modulated by the achievement of minimal residual disease negativity. Blood 136:12-13 [Abstract #720, ASH 2020 62nd Meeting].","DOI":"10.1182\/blood-2020-137075"},{"key":"633_CR25","doi-asserted-by":"crossref","unstructured":"\u2022 Sanoja-Flores L, Flores-Montero J, Puig N, et al. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. Blood. 2019;134:2218\u201322. This paper focuses on peripheral blood (PB) MRD assessment with next-generation flow (NGF), as compared with bone marrow (BM) MRD assessment. Up to now, these data have revealed a lower sensitivity and inferiority of PB assessment compared to BM assessment.","DOI":"10.1182\/blood.2019002610"},{"key":"633_CR26","doi-asserted-by":"crossref","unstructured":"\u2022 Mazzotti C, Buisson L, Maheo S, et al. Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow. Blood Adv. 2018;2:2811\u20133 This paper focuses on peripheral blood (PB) MRD assessment with next-generation sequencing (NGS), as compared with bone marrow (BM) MRD assessment. Up to now, these data have revealed a lower sensitivity and inferiority of PB assessment compared to BM assessment.","DOI":"10.1182\/bloodadvances.2018025197"},{"key":"633_CR27","doi-asserted-by":"crossref","unstructured":"\u2022 Murray DL, Puig N, Kristinsson S, et al. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders\u00a0: an International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer J. 2021:4\u20139 A first report by the International Myeloma Working Group (IMWG) on the possible role of mass spectrometry (MS) in plasma cell disorders.","DOI":"10.1038\/s41408-021-00408-4"},{"key":"633_CR28","doi-asserted-by":"crossref","unstructured":"Zajec M, Langerhorst P, Noori S, et al (2020) Minimal residual disease in multiple myeloma: targeted mass spectrometry in blood vs next generation sequencing in bone marrow. Blood 136:9 [Abstract #3156, ASH 2020 62nd Meeting].","DOI":"10.1182\/blood-2020-139330"},{"key":"633_CR29","doi-asserted-by":"crossref","unstructured":"Pu\u00edg N, Contreras T, Paiva B, et al (2020) Analysis of treatment efficacy in the GEM-CESAR trial for high-risk smoldering multiple myeloma patients: comparison between the standard and IMWG MRD criteria and QIP-MS including FLC (QIP-FLC-MS). J Clin Oncol 38: Abstract #8512 [ASCO 2020 Annual Meeting].","DOI":"10.1200\/JCO.2020.38.15_suppl.8512"},{"key":"633_CR30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1182\/blood-2020-141342","volume":"136","author":"B Nandakumar","year":"2020","unstructured":"Nandakumar B, Murray DL, Dispenzieri A, Kapoor P, Buadi FK, Lacy MQ, et al. Sequential comparison of conventional serum immunofixation (IFE) to mass spectrometry-based assessment (MASS FIX) in patients with multiple myeloma (MM). Blood. 2020;136:12\u20133.","journal-title":"Blood"},{"key":"633_CR31","doi-asserted-by":"crossref","unstructured":"Eveillard M, Rustad E, Roshal M, Zhang Y, Ciardiello A, Korde N, et al. Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma. Br J Haematol. 2020;189:904\u20137.","DOI":"10.1111\/bjh.16443"},{"key":"633_CR32","doi-asserted-by":"crossref","unstructured":"Abeykoon JP, Murray DL, Murray I, Jevremovic D, Otteson GE, Dispenzieri A, et al. Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma. Br J Haematol. 2021;193:380\u20135.","DOI":"10.1111\/bjh.17195"},{"key":"633_CR33","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1200\/JCO.2006.08.5803","volume":"25","author":"R Walker","year":"2007","unstructured":"Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD Jr, et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol. 2007;25:1121\u20138.","journal-title":"J Clin Oncol"},{"key":"633_CR34","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/bjh.14401","volume":"176","author":"A Latifoltojar","year":"2017","unstructured":"Latifoltojar A, Hall-Craggs M, Rabin N, Popat R, Bainbridge A, Dikaios N, et al. Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response. Br J Haematol. 2017;176:222\u201333.","journal-title":"Br J Haematol"},{"key":"633_CR35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1148\/radiol.2019181949","volume":"291","author":"C Messiou","year":"2019","unstructured":"Messiou C, Hillengass J, Delorme S, Lecouvet FE, Moulopoulos LA, Collins DJ, et al. Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: myeloma response assessment and diagnosis system (MY-RADS). Radiology. 2019;291:5\u201313.","journal-title":"Radiology"},{"key":"633_CR36","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1038\/s41375-019-0496-7","volume":"33","author":"M Br\u00fcggemann","year":"2019","unstructured":"Br\u00fcggemann M, Kotrov\u00e1 M, Knecht H, et al. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. Leukemia. 2019;33:2241\u201353.","journal-title":"Leukemia"},{"key":"633_CR37","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1038\/s41375-019-0508-7","volume":"33","author":"B Scheijen","year":"2019","unstructured":"Scheijen B, Meijers RWJ, Rijntjes J, et al. Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS. Leukemia. 2019;33:2227\u201340.","journal-title":"Leukemia"},{"key":"633_CR38","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1038\/s41375-019-0499-4","volume":"33","author":"H Knecht","year":"2019","unstructured":"Knecht H, Reigl T, Kotrov\u00e1 M, et al. Quality control and quantification in IG\/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS. Leukemia. 2019;33:2254\u201365.","journal-title":"Leukemia"},{"key":"633_CR39","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/leu.2017.58","volume":"31","author":"J Martinez-Lopez","year":"2017","unstructured":"Martinez-Lopez J, Sanchez-Vega B, Barrio S, Cuenca I, Ruiz-Heredia Y, Alonso R, et al. Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma. Leukemia. 2017;31:1446\u20139.","journal-title":"Leukemia"},{"key":"633_CR40","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jmoldx.2018.10.008","volume":"21","author":"ME Arcila","year":"2019","unstructured":"Arcila ME, Yu W, Syed M, Kim H, Maciag L, Yao JJ, et al. Establishment of immunoglobulin heavy (IGH) chain clonality testing by next-generation sequencing for routine characterization of B-cell and plasma cell neoplasms. J Mol Diagnostics. 2019;21:330\u201342.","journal-title":"J Mol Diagnostics"},{"key":"633_CR41","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s00259-015-3200-9","volume":"43","author":"C Nanni","year":"2016","unstructured":"Nanni C, Zamagni E, Versari A, Chauvie S, Bianchi A, Rensi M, et al. Image interpretation criteria for FDG PET\/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2016;43:414\u201321.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"633_CR42","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1007\/s00259-017-3909-8","volume":"45","author":"C Nanni","year":"2018","unstructured":"Nanni C, Versari A, Chauvie S, Bertone E, Bianchi A, Rensi M, et al. Interpretation criteria for FDG PET\/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2018;45:712\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"633_CR43","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1200\/JCO.20.00386","volume":"39","author":"E Zamagni","year":"2021","unstructured":"\u2022 Zamagni E, Nanni C, Dozza L, et al. Standardization of 18 F-FDG\u2013PET\/CT according to Deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma. J Clin Oncol. 2021;39:116\u201325 An important step towards the standardization of positron emission tomography\/computed tomography (PET\/CT) response assessment. In a pooled analysis of two phase III trials, Zamagni et al. pinpointed the prognostic impact of response by PET\/CT following the Deauville criteria.","journal-title":"J Clin Oncol"},{"key":"633_CR44","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1200\/JCO.20.01814","volume":"39","author":"H Avet-Loiseau","year":"2021","unstructured":"Avet-Loiseau H, San-Miguel J, Casneuf T, Iida S, Lonial S, Usmani SZ, et al. Evaluation of sustained minimal residual disease negativity with daratumumab-combination regimens in relapsed and\/or refractory multiple myeloma: analysis of POLLUX and CASTOR. J Clin Oncol. 2021;39:1139\u201349.","journal-title":"J Clin Oncol"},{"key":"633_CR45","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood-2020-137109","volume":"136","author":"JL Kaufman","year":"2020","unstructured":"Kaufman JL, Laubach JP, Sborov D, Reeves B, Rodriguez C, Chari A, et al. Daratumumab (DARA) Plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): updated analysis of Griffin after 12 months of maintenance therapy. Blood. 2020;136:45\u20136.","journal-title":"Blood"},{"key":"633_CR46","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","volume":"35","author":"J-J Lahuerta","year":"2017","unstructured":"Lahuerta J-J, Paiva B, Vidriales M-B, Cord\u00f3n L, Cedena MT, Puig N, et al. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials. J Clin Oncol. 2017;35:2900\u201310.","journal-title":"J Clin Oncol"},{"key":"633_CR47","unstructured":"U.S. Department of Health and Human Services - Food and Drug Administration. Clinical trial endpoints for the approval of cancer drugs and biologics. Guidance for Industry. Silver Spring, US-MD: Guidance for Industry; 2018."},{"key":"633_CR48","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.bbmt.2019.09.015","volume":"26","author":"SA Holstein","year":"2020","unstructured":"Holstein SA, Al-Kadhimi Z, Costa LJ, et al. Summary of the third annual blood and marrow transplant clinical trials network myeloma intergroup workshop on minimal residual disease and immune profiling. Biol Blood Marrow Transplant. 2020;26:e7\u2013e15.","journal-title":"Biol Blood Marrow Transplant"},{"key":"633_CR49","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1158\/1078-0432.CCR-20-0951","volume":"26","author":"M D\u2019Agostino","year":"2020","unstructured":"D\u2019Agostino M, Zaccaria GM, Ziccheddu B, et al. Early relapse risk in patients with newly diagnosed multiple myeloma characterized by next-generation sequencing. Clin Cancer Res. 2020;26:4832\u201341.","journal-title":"Clin Cancer Res"},{"key":"633_CR50","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1038\/s41375-018-0142-9","volume":"32","author":"A Larocca","year":"2018","unstructured":"Larocca A, Dold SM, Zweegman S, Terpos E, W\u00e4sch R, D\u2019Agostino M, et al. Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia. 2018;32:1697\u2013712.","journal-title":"Leukemia"},{"key":"633_CR51","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1080\/14737140.2018.1496823","volume":"18","author":"M Salvini","year":"2018","unstructured":"Salvini M, D\u2019Agostino M, Bonello F, Boccadoro M, Bringhen S. Determining treatment intensity in elderly patients with multiple myeloma. Expert Rev Anticancer Ther. 2018;18:917\u201330.","journal-title":"Expert Rev Anticancer Ther"},{"key":"633_CR52","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21:1630\u201342.","journal-title":"Lancet Oncol"},{"key":"633_CR53","doi-asserted-by":"crossref","unstructured":"Gay F, Musto P, Rota-Scalabrini D, et al (2020) Survival analysis of newly diagnosed transplant-eligible multiple myeloma patients in the randomized forte trial. Blood 136:35-37 [Abstract #141, ASH 2020 62nd Meeting].","DOI":"10.1182\/blood-2020-136907"},{"key":"633_CR54","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.critrevonc.2018.09.008","volume":"132","author":"M D\u2019Agostino","year":"2018","unstructured":"D\u2019Agostino M, De Paoli L, Conticello C, et al. Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: a pooled analysis of 2 phase III trials. Crit Rev Oncol Hematol. 2018;132:9\u201316.","journal-title":"Crit Rev Oncol Hematol"},{"key":"633_CR55","doi-asserted-by":"publisher","unstructured":"Larocca A, Bonello F, Gaidano G, D'Agostino M, Offidani M, Cascavilla N, et al. Dose\/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit, newly diagnosed multiple myeloma patients. Blood. 2021; online ahead of print. https:\/\/doi.org\/10.1182\/blood.2020009507.","DOI":"10.1182\/blood.2020009507"},{"key":"633_CR56","doi-asserted-by":"crossref","unstructured":"D\u2019Agostino M, Bertamini L, Oliva S, Boccadoro M, Gay F. Pursuing a curative approach in multiple myeloma: a review of new therapeutic strategies. Cancers (Basel). 2019;11:2015.","DOI":"10.3390\/cancers11122015"},{"key":"633_CR57","doi-asserted-by":"crossref","unstructured":"Mateos M-V, Martinez-Lopez J, Rodriguez Otero P, et al (2019) Curative strategy (GEM-CESAR) for high-risk smoldering myeloma (SMM): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with Krd and maintenance with Rd. Blood 134:Abstract #781 [ASH 2019 61st Meeting].","DOI":"10.1182\/blood-2019-125204"},{"key":"633_CR58","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1053\/j.seminhematol.2018.02.009","volume":"55","author":"N Pandit-Taskar","year":"2018","unstructured":"Pandit-Taskar N. Functional imaging methods for assessment of minimal residual disease in multiple myeloma: current status and novel immunoPET based methods. Semin Hematol. 2018;55:22\u201332.","journal-title":"Semin Hematol"},{"key":"633_CR59","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","volume":"123","author":"J Martinez-Lopez","year":"2014","unstructured":"Martinez-Lopez J, Lahuerta JJ, Pepin F, Gonz\u00e1lez M, Barrio S, Ayala R, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123:3073\u20139.","journal-title":"Blood"},{"key":"633_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12082322","volume":"12","author":"K Kriegsmann","year":"2020","unstructured":"Kriegsmann K, Hundemer M, Hofmeister-Mielke N, et al. Comparison of ngs and mfc methods: Key metrics in multiple myeloma mrd assessment. Cancers (Basel). 2020;12:1\u201315.","journal-title":"Cancers (Basel)"},{"key":"633_CR61","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez S, Goicoechea I, Gemenetzi K, et al (2020) Discordances between immunofixation (IFx) and minimal residual disease (MRD) assessment with next-generation flow (NGF) and sequencing (NGS) in patients (Pts) with multiple myeloma (MM): clinical and pathogenic significance. Blood 136:5-6 [Abstract #62, ASH 2020 62nd Meeting].","DOI":"10.1182\/blood-2020-136258"},{"key":"633_CR62","doi-asserted-by":"crossref","unstructured":"Sonneveld P, Broijl A, Gay F, et al (2019) Bortezomib, lenalidomide, and dexamethasone (VRd) \u00b1 daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): a multicenter, randomized, phase III study (PERSEUS). J Clin Oncol 37:Abstract #TPS8055 [ASCO 2019 Annual Meeting].","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8055"},{"key":"633_CR63","doi-asserted-by":"crossref","unstructured":"Costa LJ, Chhabra S, Godby KN, et al (2019) Daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) induction, autologous transplantation and post-transplant, response-adapted, measurable residual disease (MRD)-based Dara-Krd consolidation in patients with newly diagnosed multiple myelo. Blood 134:Abstract #860 [ASH 2019 61st Meeting].","DOI":"10.1182\/blood-2019-123170"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00633-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-021-00633-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00633-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T15:59:06Z","timestamp":1675267146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-021-00633-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["633"],"URL":"https:\/\/doi.org\/10.1007\/s11899-021-00633-5","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"6 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LB declares no competing financial interests.MD has received honoraria for lectures from Sanofi and GSK and has served on the advisory boards for GSK.FG has received honoraria from Amgen, Celgene, Janssen, Takeda, Bristol-Myers Squibb, AbbVie, and GSK and has served on the advisory boards for Amgen, Celgene, Janssen, Takeda, Bristol-Myers Squibb, AbbVie, GSK, Roche, Adaptive Biotechnologies, Oncopeptides, Bluebird, and Secura Bio.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}